IRISH

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Tuesday, October 3, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a sibling of a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Pharmaceutical, Health, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Tuesday, October 3, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Monday, October 2, 2023
General Health, Finance, Health, Professional Services, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Monday, October 2, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Monday, October 2, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Retrieved on: 
Friday, September 29, 2023
Health, Pharmaceutical, ACT, Disclosure, IRISH, Holding company, Auction, Life insurance

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022

Key Points: 
  • DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Status of person making the disclosure:
    Person acting in concert with the offeree (namely, a director of the offeree)
    (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Retrieved on: 
Friday, September 29, 2023
ACT, Disclosure, IRISH, Life insurance

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

Key Points: 
  • OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
    Owner or controller of interests and short positions disclosed, if different from 1(a)
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)
    For an opening position disclosure, state the latest practicable date prior to the disclosure
    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
  • If it is a cash offer or possible cash offer, state “N/A”
    If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Form 8.1 Opening Position Disclosure (MariaDB plc)

Retrieved on: 
Friday, September 29, 2023
Software, Technology, Networks, Data Management, ACT, IRISH, Auction, Life insurance

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

Key Points: 
  • OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE
    (a) Full name of discloser:
    (b) Owner or controller of interests and short positions disclosed, if different from 1(a):
    The naming of nominee or vehicle companies is insufficient.
  • For a trust, the trustee(s), settlor and beneficiaries must be named.
  • (c) Name of offeror/offeree in relation to whose relevant securities this form relates:
    (d) Is the discloser the offeror or the offeree?
  • (f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

Runa Capital II (GP) (“Runa”) Statement by Runa regarding corporate governance concerns at MariaDB plc and shareholder engagement

Retrieved on: 
Thursday, September 28, 2023
MAKE, ACT, The Takeover Panel, Rationalization, Communication, Irish Takeover Panel, NOT, FOR, Central bank, OR, MariaDB, EGM, Central Bank of Ireland, Person, Open position, Schedule, Schedule 13D, MADE, Acquisition, Nature, ANY, FIRM, Davy, Knowledge, IRISH, Security (finance), Runa Capital, Disclosure, Proxy, Holding company, Bank, Cryptocurrency, Property management

Dublin, Ireland, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Runa has, for a number of years, expressed serious concerns regarding the management of (“MariaDB” or the “Company”) by its directors (the “Board”). In that context, Runa has advocated for changes to the Company’s strategic direction, including a rationalization of the Company’s budget and potentially changes in senior roles in the Company. Recently, Runa became aware that the Company intended to engage in a highly dilutive equity transaction to fund its capital needs. Runa believes that such transaction would result in substantial and damaging dilution to shareholders and would not be in the interests of the Company or its shareholders.

Key Points: 
  • Dublin, Ireland, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Runa has, for a number of years, expressed serious concerns regarding the management of (“MariaDB” or the “Company”) by its directors (the “Board”).
  • Recently, Runa became aware that the Company intended to engage in a highly dilutive equity transaction to fund its capital needs.
  • As a result, Runa is considering what further steps it may take to effect strategic change at MariaDB.
  • Runa invites discussion with MariaDB shareholders who share its concerns and are prepared to join it in requisitioning an EGM.